iShares Ethereum Trust - iShares Ethereum Trust ETF 주식 (NASDAQ: ETHA)

에 대한 최신 뉴스 iShares Ethereum Trust - iShares Ethereum Trust ETF (NASDAQ:ETHA) 주식

Goldman Sachs offices

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

ETHA

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

Fidelity Ethereum Fund Fidelity Ethereum Fund

FETH

GBTC

IBIT

거대 투자은행 골드만삭스(NYSE:GS)가 최근 미국 증권거래위원회(SEC)에 제출한 자료에 따르면, 2024년 4분기에 비트코인(CRYPTO: BTC) 및 이더리움(CRYPTO: ETH) 현물 ETF 주식을 더 많이 매입한 것으로 나타났다.

골드만삭스: 4분기 비트코인 ETF 보유액 15억 6천만 달러, 이더리움 ETF도 급증

What Happened

General

암호화폐 인덱스 펀드 운용사인 비트와이즈 에셋 매니지먼트(Bitwise Asset Management)는 수요일(22일)에 도지코인 ETF를 신청했다. 애널리스트들은 개를 테마로 하는 도지코인의 대폭 상승을 예상하고 있다.

2025년 도지코인 ETF 승인에 대한 베팅 급증, 트레이더 &#34;4,000% 상승 가능&#34;

Bitcoin and Ethereum Photo by Marisha on Shutterstock

Sector ETFs

ETFs

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

ETHV

비트코인(CRYPTO: BTC)과 이더리움(CRYPTO: ETH) 현물 ETF는 지난 4일 동안 각각 32억 6천만 달러와 7,443만 달러의 유입을 기록했다.

비트코인·이더리움 ETF, 시장 변동성과 정책 불확실성에도 기록적 자금 유입 발생

iShares Ethereum Trust - iShares Ethereum Trust ETF

Ethan Allen Interiors Inc

Doman Building Materials (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DBM#TSX">DBM</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.12 by 125 percent. This is a 68.75 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $793.20 million which beat the analyst consensus estimate of $757.38 million by 4.73 percent. This is a 31.66 percent increase over sales of $602.48 million the same period last year.

Earnings

Earnings Beats

TSX:DBM

Doman Building Materials Q1 Adj. EPS $0.27 Beats $0.12 Estimate, Sales $793.20M Beat $757.38M Estimate

Guidance

NNBR

CORRECTION: NN Lowers FY2025 Sales Guidance To $430.00M-$460.00M vs $454.30M Est

Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) affirms FY2025 Adj EPS guidance from $6.64-$7.28 to $6.64-$7.28 vs $6.97 analyst estimate. Affirms FY2025 sales outlook from $1.44 billion-$1.50 billion to $1.44 billion-$1.50 billion vs $1.46 billion estimate.

Ziff Davis Affirms FY2025 Adj EPS Guidance of $6.64-$7.28 vs $6.97 Est; Affirms FY2025 Sales Guidance of $1.44B-$1.50B vs $1.46B Est

Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) affirms FY2025 sales outlook from $460.67 million-$469.12 million to $460.67 million-$469.12 million vs $461.42 million estimate.

Karat Packaging Reiterating FY2025 guidance on net sales, gross margin and adjusted EBITDA margin.

Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) reported quarterly earnings of $1.14 per share which missed the analyst consensus estimate of $1.25 by 8.8 percent. This is a 10.24 percent decrease over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $328.64 million which beat the analyst consensus estimate of $324.19 million by 1.37 percent. This is a 4.50 percent increase over sales of $314.49 million the same period last year.

Earnings Misses

Ziff Davis Q1 Adj. EPS $1.14 Misses $1.25 Estimate, Sales $328.64M Beat $324.19M Estimate

Canacol Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNE#TSX">CNE</a>) reported quarterly earnings of $0.93 per share. This is a 745.45 percent increase over earnings of $0.11 per share from the same period last year. The company reported $72.73 million in sales this quarter. This is a 6.38 percent decrease over sales of $77.69 million the same period last year.

TSX:CNE

Canacol Energy Q1 EPS $0.93 Up From $0.11 YoY, Sales $72.73M Down From $77.69M YoY

Across the recent three months, 4 analysts have shared their insights on Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $8.25, with a high estimate of $9.00 and a low estimate of $8.00. Holding firm without variation, the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741664_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Generation Bio by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Generation Bio. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Generation Bio compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Generation Bio's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Generation Bio's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GBIO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Generation Bio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Generation Bio</h2>
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
<h3>Unraveling the Financial Story of Generation Bio</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Generation Bio's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.52% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Generation Bio's net margin excels beyond industry benchmarks, reaching -510.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Generation Bio's ROE excels beyond industry benchmarks, reaching -22.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Generation Bio's ROA excels beyond industry benchmarks, reaching -8.91%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.09, Generation Bio adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

GBIO

Where Generation Bio Stands With Analysts

10 analysts have expressed a variety of opinions on MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for MarketAxess Holdings, presenting an average target of $235.7, a high estimate of $295.00, and a low estimate of $191.00. Observing a 0.08% increase, the current average has risen from the previous average price target of $235.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741652_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of MarketAxess Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$240.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$226.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$213.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$295.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$232.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Eli Abboud</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$191.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$235.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MarketAxess Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MarketAxess Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of MarketAxess Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into MarketAxess Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MKTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MarketAxess Holdings analyst ratings.</a>
<h2>Get to Know MarketAxess Holdings Better</h2>
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
<h3>Understanding the Numbers: MarketAxess Holdings's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: MarketAxess Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 2.61%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MarketAxess Holdings's net margin excels beyond industry benchmarks, reaching 32.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): MarketAxess Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.69%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): MarketAxess Holdings's ROA excels beyond industry benchmarks, reaching 3.6%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.05, MarketAxess Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MKTX

The Analyst Verdict: MarketAxess Holdings In The Eyes Of 10 Experts

11 analysts have shared their evaluations of Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $170.82, along with a high estimate of $201.00 and a low estimate of $142.00. This current average has decreased by 9.18% from the previous average price target of $188.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741643_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Ares Management by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$161.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$156.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$201.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$187.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ares Management. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ares Management compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ares Management's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ares Management's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARES/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ares Management analyst ratings.</a>
<h2>Get to Know Ares Management Better</h2>
Ares Management Corp is an asset management company. It offers investors investment-related advice and strategies for capital growth. The company's operating segments include Credit Group, Private Equity Group, Real Assets, Secondaries Group, and Others. Its Credit Group generates maximum revenue and manages credit strategies across the liquid and illiquid spectrum. Private Equity Group manages investment strategies categorized as corporate private equity, infrastructure and power, and special opportunities, Real Estate Group manages comprehensive equity and debt strategies across real estate &amp; infrastructure investments. The Secondaries Group invests in secondary markets across a range of alternative asset class strategies, including private equity, real estate, infrastructure, &amp; credit.
<h3>Unraveling the Financial Story of Ares Management</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Ares Management's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 19.45%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Ares Management's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3.39%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.05%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ares Management's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.17%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ares Management's debt-to-equity ratio stands notably higher than the industry average, reaching 6.31. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARES

Assessing Ares Management: Insights From 11 Financial Analysts

i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) lowers FY2025 Adj EPS guidance from $1.05-$1.25 to $0.96-$1.06 vs $1.17 analyst estimate. Lowers FY2025 sales outlook from $243.00 million-$263.00 million to $207.00 million-$217.00 million vs $250.53 million estimate.

IIIV

i3 Verticals Lowers FY2025 Adj EPS Guidance from $1.05-$1.25 to $0.96-$1.06 vs $1.17 Est; Lowers FY2025 Sales Guidance from $243.00M-$263.00M to $207.00M-$217.00M vs $250.53M Est

In the preceding three months, 5 analysts have released ratings for CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $186.0, a high estimate of $210.00, and a low estimate of $160.00. A decline of 12.35% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741636_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of CDW's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$205.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CDW. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CDW compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for CDW's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of CDW's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CDW analyst ratings.</a>
<h2>Get to Know CDW Better</h2>
CDW Corp is a multi-brand provider of information technology ("IT") solutions to small, medium, and large business, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's broad array of offerings ranges from discrete hardware and software products to integrated IT solutions and services that include on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. The company has five operating segments namely, Corporate, Small Business, Public, CDW UK, and CDW Canada. The Corporate segment generates the majority of its revenue and serves USA private sector business customers.
<h3>CDW's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: CDW displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.34%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CDW's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.09% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): CDW's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.24% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.82%, the company showcases effective utilization of assets.
Debt Management: CDW's debt-to-equity ratio stands notably higher than the industry average, reaching 2.55. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDW Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Looking into the current session, CPI Card Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) shares are trading at $19.85, after a 1.64% decrease. Over the past month, the stock fell by 6.29%, but over the past year, it actually went up by 0.96%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1746741627_0.png" alt="Past Year Chart" />

<h3>Evaluating CPI Card P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
CPI Card has a lower P/E than the aggregate P/E of 25.28 of the Technology Hardware, Storage &amp; Peripherals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746741628_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

PMTS

P/E Ratio Insights for CPI Card

During the last three months, 4 analysts shared their evaluations of Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $18.12, with a high estimate of $20.00 and a low estimate of $16.00. Surpassing the previous average price target of $17.12, the current average has increased by 5.84%.
<img src="https://www.benzinga.com/files/images/story/2025/1746741623_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Pediatrix Medical Group is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pediatrix Medical Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pediatrix Medical Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pediatrix Medical Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pediatrix Medical Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Pediatrix Medical Group: A Closer Look</h2>
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
<h3>Key Indicators: Pediatrix Medical Group's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Pediatrix Medical Group faced challenges, resulting in a decline of approximately -7.42% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.52%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Pediatrix Medical Group's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.67%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Pediatrix Medical Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.0%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pediatrix Medical Group's debt-to-equity ratio is below the industry average. With a ratio of 0.83, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Pediatrix Medical Group Through The Eyes Of 4 Analysts

Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) has outperformed the market over the past 10 years by 3.0% on an annualized basis producing an average annual return of 13.4%. Currently, Martin Marietta Materials has a market capitalization of $33.02 billion. 
Buying $100 In MLM: If an investor had bought $100 of MLM stock 10 years ago, it would be worth $359.24 today based on a price of $541.56 for MLM at the time of writing.
<h3>Martin Marietta Materials's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746741617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Martin Marietta Materials 10 Years Ago Would Be Worth Today

10 analysts have expressed a variety of opinions on Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.4, along with a high estimate of $33.00 and a low estimate of $24.00. Witnessing a positive shift, the current average has risen by 5.19% from the previous average price target of $27.00.
<img src="https://www.benzinga.com/files/images/story/2025/1746741613_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Remitly Global is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Philip Gibbs</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Remitly Global. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Remitly Global compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Remitly Global's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Remitly Global's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RELY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Remitly Global analyst ratings.</a>
<h2>All You Need to Know About Remitly Global</h2>
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
<h3>Financial Milestones: Remitly Global's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Remitly Global's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 32.91%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Remitly Global's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1.63%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Remitly Global's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.88%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Remitly Global's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.58%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RELY

Analyst Expectations For Remitly Global's Future

FTAI Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIP#NASDAQ">FIP</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.29) by 68.97 percent. This is a 83.33 percent increase over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $96.16 million which missed the analyst consensus estimate of $107.83 million by 10.82 percent. This is a 16.51 percent increase over sales of $82.53 million the same period last year.

FTAI Infrastructure Q1 Adj. EPS $(0.09) Beats $(0.29) Estimate, Sales $96.16M Miss $107.83M Estimate

i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.30 by 6.67 percent. This is a 5.88 percent decrease over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $63.06 million which missed the analyst consensus estimate of $64.12 million by 1.66 percent. This is a 33.30 percent decrease over sales of $94.54 million the same period last year.

i3 Verticals Q2 Adj. EPS $0.32 Beats $0.30 Estimate, Sales $63.06M Miss $64.12M Estimate

Bitcoin miner CleanSpark Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) reported first-quarter financial results after the market close on Thursday. Here&#8217;s an overview <a href="https://www.benzinga.com/pressreleases/25/05/n45299285/cleanspark-reports-second-quarter-fiscal-2025-results">of the report</a>.
Q1 Earnings: CleanSpark reported first-quarter revenue of $181.71 million, missing analyst estimates of $190.95 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported a first-quarter loss of 49 cents per share, missing estimates for a loss of eight cents per share.
Total revenue was up 62.5% year-over-year. CleanSpark said it mined 1,957 Bitcoin in the quarter and ended the period with $979.6 million in total Bitcoin holdings. The company also had $97 million in cash at the quarter&#8217;s end.
&#8220;This was a quarter defined by discipline, scale and continued strategic clarity. As other players shift direction or decelerate growth, CleanSpark has doubled down on being the only remaining pure-play, public&nbsp;Bitcoin&nbsp;miner,&#8221; said&nbsp;Zach Bradford, CEO of CleanSpark.
&#8220;We believe that focus matters now more than ever, and we remain on track to reach our 50 EH/s target during June, all while growing our&nbsp;Bitcoin&nbsp;treasury, strengthening the balance sheet, and prioritizing long-term stockholder value.&#8221;
CLSK Price Action: <a href="http://benzinga.com/quote/clsk">CleanSpark shares</a> were down 4.95% in Thursday&#8217;s after-hours session, trading at $8.25 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45303574/mara-holdings-stock-dips-after-worse-than-expected-q1-report">Mara Holdings Stock Dips After Worse-Than-Expected Q1 Report</a></li>
</ul>
Photo: creativeneko/Shutterstock.

Movers

CLSK

Bitcoin Miner CleanSpark Misses Q1 Earnings Estimates, Company On Track To Reach 50 EH/s Target In June, Shares Slide

IGM Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IGM#TSX">IGM</a>) reported quarterly earnings of $1.00 per share. This is a 6.38 percent increase over earnings of $0.94 per share from the same period last year. The company reported $875.80 million in sales this quarter. This is a 7.90 percent increase over sales of $811.67 million the same period last year.

TSX:IGM

IGM Financial Q1 Adj. EPS $1.00 Up From $0.94 YoY, Sales $875.80M Up From $811.67M YoY

Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 12 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $1.08 million which missed the analyst consensus estimate of $1.27 million by 15.12 percent. This is a 9.28 percent increase over sales of $986.46 thousand the same period last year.

DPRO

Draganfly Q1 EPS $(0.44) Beats $(0.48) Estimate, Sales $1.08M Miss $1.27M Estimate

Press Releases

BlackRock's ETHA Debuts on Nasdaq

거대 투자은행 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)가 최근 미국 증권거래위원회(SEC)에 제출한 자료에 따르면, 2024년 4분기에 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 및 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 현물 ETF 주식을 더 많이 매입한 것으로 나타났다.
무슨 일 있었나: 골드만삭스는 Fidelity Wise Origin Bitcoin Fund(BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>) 353만 주, 즉 2억 8,810만 달러에 달하는 상당한 지분을 보유하고 있다고 보고했다. 12월 31일로 끝나는 4분기에 추가로 180만 주를 매입했다.
또한 세계 최대 비트코인 펀드인 iShares Bitcoin Trust ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) 1,130만 주를 추가로 매입한 후 노출을 12억 7,000만 달러로 늘렸다.
흥미롭게도 골드만삭스는 ARK 21Shares Bitcoin ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>)의 전체 지분을 매각하고 Grayscale Bitcoin ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#NYSE">GBTC</a>)에 대한 노출을 축소했다.
골드만삭스의 총 비트코인 ETF 보유액은 3분기에 보고된 7억 1천만 달러에서 <a href="https://www.benzinga.com/24/11/42029764/global-banks-jp-morgan-goldman-sachs-add-to-bitcoin-ethere-etf-positions-in-q3-morgan-stanley-increases-microstrategy-stake-to-16b">15억 6천만</a> 달러로 증가했다.
그리고 골드만삭스는 이더리움 현물 ETF 포지션도 추가했다.
처음으로 골드만삭스는 iShares Ethereum Trust ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>)에 대한 노출을 추가하여 931만 주, 즉 2억 3,550만 달러 상당을 매입했다. 또한 Fidelity Ethereum Fund(BATS:<a class="ticker" href="https://www.benzinga.com/stock/FETH#BATS">FETH</a>)에 대한 지분을 2억 3,469만 달러로 늘렸다고 보고했다.
골드만삭스의 총 이더리움 ETF 보유액은 4분기 말 4억 7,650만 달러로 전기의 2,500만 달러 대비 대폭 증가했다.
주가 움직임: <a href=""https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.."">벤징가 프로 데이터에</a> 따르면 화요일 정규장에서 골드만삭스 주가는 0.51% 하락한 647.24달러로 마감했다. 올해 들어 주가는 13.03% 상승했다.
사진 제공: Shutterstock.com
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

암호화폐 인덱스 펀드 운용사인 비트와이즈 에셋 매니지먼트(Bitwise Asset Management)는 수요일(22일)에 도지코인 ETF를 신청했다. 애널리스트들은 개를 테마로 하는 도지코인의 대폭 상승을 예상하고 있다.
무슨 일 있었나: 비트와이즈는 델라웨어주 국무부 기업부에 <a href="https://icis.corp.delaware.gov/eCorp/EntitySearch/NameSearch.aspx?_=1737585406503" target="_blank" rel="noopener">ETF 서류를 제출했다.</a> 이 서류는 &#8216;비트와이즈 도지코인 ETF&#8216;(BITWISE DOGECOIN ETF)라는 법인명으로 제출되었으며, CSC 델라웨어 트러스트 컴퍼니(CSC Delaware Trust Company)가 등록 대리 기관으로 등재되었다.
비트와이즈는 벤징가의 제출 확인 요청에 즉시 응답하지 않았지만, 수석 ETF 애널리스트 에릭 발추나스는 소셜미디어 엑스(X)에서 제출이 합법적이라고 전했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Bitwise Doge ETF likely coming soon.. and yes I checked and this is def legit (vs some whack job committing forgery for a quick pump a la BlackRock XRP that one time). <a href="https://t.co/MxoswD0IFy">pic.twitter.com/MxoswD0IFy</a>
&mdash; Eric Balchunas (@EricBalchunas) <a href="https://twitter.com/EricBalchunas/status/1882202309293433217?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
델라웨어주 등록은 일반적으로 ETF 상장 절차의 첫 단계이며, 증권거래위원회(SEC)에 공식적으로 신고해야 한다.
이전에 iShares Bitcoin Trust ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>)와 iShares Ethereum Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>)도 비슷한 상장 과정을 거쳤다. 그리고 작년에 비트와이즈가 신청한 <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41134111/after-bitcoin-ethereum-an-xrp-etf-bitwise-registers-filing-in-delaware-amid-rippe-vs-sec-l" target="_blank" rel="noopener">XRP ETF도</a> 마찬가지다.
ETF 신청 후, 유명한 암호화폐 애널리스트이자 트레이더인 알리 마르티네즈는 도지코인에 대해 15달러라는 엄청난 강세 목표가를 제시했다. 현재 가격 대비 4,140.88%의 엄청난 상승 여력을 의미한다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> ETF will send it to $15! <a href="https://t.co/4peKi93NZX">https://t.co/4peKi93NZX</a> <a href="https://t.co/gRqDdoXhob">pic.twitter.com/gRqDdoXhob</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1882196406800445537?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
왜 중요한가: 비트와이즈의 등록은 이번 주 초 렉스셰어스(REXShares)와 오스프레이(Osprey)가 <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43105356/meme-coin-supercycle-dogecoin-trump-bonk-futures-etf-applications-filed" target="_blank" rel="noopener">도지코인 ETF를 포함하여</a> 수많은 ETF 신청서를 SEC에 제출한 이후 이루어졌다.
이러한 신청은 예측 시장에 반영되어, 2025년에 도지코인 ETF가 승인될 확률이 폴리마켓에서 <a href="https://polymarket.com/event/doge-etf-approved-in-2025" target="_blank" rel="noopener">36%에서 53%로 상승</a>했으며, 현재 이 기사를 작성하는 시점에는 48%로 안정화되었다.
한편, 도지코인의 인기와 밀접한 관련이 있는 상징인 시바견 이미지는 일론 머스크가 이끄는 정부효율부 웹사이트에서 <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43140690/dogecoin-drops-6-after-doge-department-removes-logo" target="_blank" rel="noopener">삭제되었다</a>.
가격 움직임: <a href=""https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.."">벤징가 프로 데이터에</a> 따르면 기사 작성 시점에 도지코인은 지난 24시간 동안 3.07% 하락한 0.3535달러에 거래되고 있었다. 올해 들어 도지코인은 8.43% 상승했다.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter">
<div class="wp-block-embed__wrapper"></div>
</figure>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

2025년 도지코인 ETF 승인에 대한 베팅 급증, 트레이더 "4,000% 상승 가능"

비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 현물 <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener">ETF</a>는 지난 4일 동안 각각 32억 6천만 달러와 7,443만 달러의 유입을 기록했다. 이러한 급격한 유입은 도널드 트럼프 대통령이 취임 연설에서 암호화폐 언급을 생략한 이후 암호화폐 시장의 변동성이 커졌음에도 불구하고 발생했다.
소소밸류(Sosovalue) 데이터에 따르면 기록적인 ETF로의 자금 유입은 1월 17일에 발생했다. 약 10억 8천만 달러가 다양한 비트코인 펀드로 유입되었다. 또한 1월 21일에는 8억 2,250만 달러가 유입되었다.
<h3 class="wp-block-heading">비트코인 ETF</h3>
<ul>
<li>블랙록의 iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>): 최대 순 유입액 6억 6,186만 달러 기록</li>
<li>그레이스케일의 Bitcoin Mini Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTC#NYSE">BTC</a>): 1억 3,639만 달러 유입</li>
<li>ARK 21Shares Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#NYSE">ARKB</a>): 851만 달러 유입</li>
<li>Fidelity Wise Origin Bitcoin Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>): 697만 달러 유입</li>
</ul>
이러한 추세와는 다르게 Bitwise의 Bitcoin ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITB#NYSE">BITB</a>)에서는 이날 1,741만 달러의 자금이 유출되었다.
비트코인 현물 ETF는 총 1,359억 달러의 순자산 가치를 관리하고 있으며, 비트코인 전체 시장 가치의 약 5.88%에 해당하는 금액이다.
<h3 class="wp-block-heading">이더리움 ETF</h3>
<ul>
<li>블랙록의 iShares Ethereum Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>): 최대 순 유입액 5,631만 달러 기록</li>
<li>그레이스케일의 Ethereum Mini Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETH#NYSE">ETH</a>): 1,249만 달러 유입</li>
<li>VanEck Ethereum ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ETHV#BATS">ETHV</a>): 365만 달러 유입</li>
<li>Fidelity의 Ethereum Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FETH#BATS">FETH</a>): 332만 달러 유입</li>
</ul>
현재 9개의 이더리움 현물 ETF가 120억 7천만 달러의 자산을 관리하고 있으며, 이는 이더리움 시가총액의 약 3%에 해당한다.
트럼프 대통령이 취임 연설에서 암호화폐에 대한 언급을 자제하면서 비트코인은 연설 전 106,000달러에서 연설 중 101,000달러까지 하락했고, 현재 104,000달러를 기록하고 있다.
솔라나 역시 압박을 받아 사상 최고치에서 거의 10% 하락했다. 투자자들은 암호화폐의 미래에 대한 장기적인 비전에 베팅하고 이를 암호화폐 세계로 진입할 기회로 삼고 있을 수 있다.
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

최근 증권거래위원회(SEC)에 제출된 13F 공시에 따르면, 글로벌 투자은행들이 암호화폐 관련 상장지수펀드(ETF)와 비트코인 대리 종목인 마이크로스트레티지에 대해 상당한 지분을 보유하고 있다는 사실이 밝혀졌다.
<h3>JP모건 체이스</h3>
시가총액 기준 세계 최대 은행인 JP모건 체이스는 9월 30일 마감 분기에 비트코인과 이더리움 ETF에 상당한 투자를 했다.
JP모건은 iShares Bitcoin Trust ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) 387주를 13,982달러에 매입했는데, 이는 지난 분기에 모두 매도한 후 다시 매입한 것이다. 또한 Fidelity Wise Origin Bitcoin Fund(BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>)에도 자금을 재할당해 213주를 11,877달러에 매입했다.
전반적으로 JP모건의 비트코인 ETF 노출액은 거의 65,000달러에 달했다.
그리고 JP모건은 처음으로 이더리움 ETF에 진입하면서 Grayscale Ethereum Trust ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETHE#NYSE">ETHE</a>)와 그 미니 버전인 Grayscale Ethereum Mini Trust ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETH#NYSE">ETH</a>)에 상당한 투자를 했다. 두 펀드에 대한 총 투자액은 30,700달러였다.
암호화폐 노출을 늘리려는 시도 속에서 JP모건은 마이크로스트레티지 포트폴리오를 12.5% 증가시켜 660,693주로 늘렸고, 이는 1억 1,139만 달러에 달한다.
<h3>골드만삭스</h3>
또 다른 월가 거대 은행인 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)는 지난주 13F 서류를 제출했다.
골드만삭스는 여러 비트코인 ETF에 7억 1천만 달러를 투자했으며 IBIT 펀드 1,270만 주를 보유하고 있고 이는 <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40410418/goldman-sachs-makes-blockbuster-debut-adds-over-400m-in-bitcoin-etf-position-in-q2-as-morg" target="_blank" rel="noopener">4억 6,100만 달러에 해당</a>한다고 공개했다.
이러한 투자로 골드만삭스는 IBIT 펀드의 제2대 주주가 되었으며, 현재 세계 최대 비트코인 투자펀드인 IBIT의 자산은 428억 9,000만 달러에 달한다.
한편, 골드만삭스는 2,516만 달러 규모의 이더리움 ETF를 보유하고 있으며, 이는 Grayscale의 Mini Trust(ETH)와 Fidelity의 이더리움 펀드(BATS:<a class="ticker" href="https://www.benzinga.com/stock/FETH#BATS">FETH</a>)에 분산되어 있다.
흥미롭게도, 골드만삭스는 3분기에 약 534,894주의 마이크로스트레티지 주식을 매각하여 보유 비중을 1억 4,044만 달러로 줄였다.
<h3>모건 스탠리</h3>
모건스탠리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)는 지난 분기에 비트코인 ETF 포트폴리오 규모를 2억 3,300만 달러에서 1억 8,339만 달러로 줄였다.
이러한 자금 유출은 주식 449,802주의 IBIT 펀드 주식을 매도한 데 따른 것이었다.
또한 모건스탠리는 이더리움 ETF에 투자했는데 주로 iShares Ethereum Trust ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>)를 통한 투자였다.
한편, 마이크로스트레티지 보유량은 22.6% 증가한 9,595,008주로 16억 1,100만 달러에 달했다.
사진 출처: Avi Rozen on Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

iShares Ethereum Trust - iShares Ethereum Trust ETF

뉴스

에 대한 최신 뉴스 iShares Ethereum Trust - iShares Ethereum Trust ETF (NASDAQ:ETHA) 주식

수요일, 2월 12, 2025

목요일, 1월 23, 2025

월요일, 11월 18, 2024

뉴스

파트너 / 기고자

벤징가 글로벌